Detection of Immune Complex Formation in Non-Clinical Studies and Implications for Clinical Risk Assessment
Steve J. Swanson, Ph.D., Executive Director, Medical Sciences, Clinical Immunology,
Fundamental Considerations for Defining “Comparable”
Therapeutic Monoclonal Antibodies
Paul Chamberlain, NDA Advisory Board
Immunogenicity Considerations in the Approval of Generic Enoxaparin in the US
Daniela Verthelyi, M.D., Ph.D., Chief, Immunology, Therapeutic Proteins, CDER/FDA
Register and view full details at: http://www.ImmunogenicitySummit.com
Stay on for Part Two: Immunogenicity Prediction and Mitigation (Oct. 11-12).
To inquire about sponsoring and/or exhibiting, contact Tim McLucas, 781-972-1342, firstname.lastname@example.org.
Writers and editors are encouraged to attend. To request a press pass, contact Lisa Scimemi at email@example.com.
About Cambridge Healthtech Institute (www.chicorporate.com)
CHI is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and CHI’s Media Group, which includes news websites and e-newsletters including Bio-IT World and eCliniqua. Founded in 1992, CHI strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments.
Cambridge Healthtech Institute